Table 1. Placebo attitudes and ways in which physicians would describe placebos to patients.
Question | % of respondents 1 | ||
---|---|---|---|
Canada | US 2 | P-value | |
I have prescribed or administered a placebo in the following situation(s): | |||
After all clinically indicated treatment possibilities were exhausted | 11 | 11 | NS |
After "unjustified" demand for medication | 8 | 15 | χ2(1) = 5.1 (P = 0.024) |
To placate or calm a patient | 13 | 18 | NS |
To control pain (including in the context of patient-controlled analgesia) | 5 | 6 | NS |
As a diagnostic tool (e.g., to distinguish between psychogenic and organic causes of symptoms) | 10 | 4 | χ2(1) = 6.5 (P = 0.011) |
As a supplemental treatment | 14 | 18 | NS |
For non-specific complaints | 12 | 13 | NS |
To stop patients from complaining | 4 | 6 | NS |
If I were to prescribe a placebo, I would tell the patient that: | |||
It is a medication | 4 | 19 | χ2(1) = 22.5 (P < 0.0001) |
It is a placebo | 11 | 4 | χ2(1) = 7.4 (P = 0.007) |
It is medicine with no specific effect | 6 | 9 | NS |
It is a substance that may help and will not harm | 35 | 34 | NS |
Other | 5 | 33 | χ2(1) = 51.6 (P < 0.0001) |
The following statement(s) best describe(s) my position on the use of placebos outside of research: | |||
The use of placebos should be categorically prohibited. | 9 | 12 | NS |
The use of placebos may be permitted if research supports its efficacy. | 44 | 46 | NS |
The use of placebos may be permitted if the experience of colleagues supports it. | 9 | 9 | NS |
The use of placebos may be permitted after notifying the patient that he/she is receiving a placebo. | 31 | 21 | χ2(1) = 5.7 (P = 0.017) |
The use of placebos may be permitted if I anticipate that it will be of benefit to the patient. | 37 | 31 | NS |
1 Sums may exceed 100% due to acceptance of multiple responses.
2 reported in Sherman et al., 2008
NS = non-significant, as determined by chi-square test